5G-PEARL: Paxalisib in Malignant Brain Tumours

This trial (called 5G-PEARL) is testing a drug called paxalisib — which blocks a signaling pathway that fuels tumor growth — in people with malignant brain tumors, primarily glioblastoma (a very aggressive form of brain cancer). The study is testing it as a front-line treatment after standard surgery and radiation, as well as in other settings. **You may be eligible if...** - You have been diagnosed with glioblastoma (WHO Grade IV, IDH-wildtype) or another high-grade malignant brain tumor - You have completed standard treatment (surgery and/or radiation) and have minimal remaining disease (minimal residual disease cohort) or are in another phase of the study - You have had comprehensive genomic testing done (whole genome sequencing) as part of the Minderoo Precision Brain Tumour Programme or NHS-funded program - You are in reasonably good health with adequate organ function **You may NOT be eligible if...** - You have had prior treatment with paxalisib or similar PI3K/mTOR pathway inhibitors - You have uncontrolled diabetes or other serious metabolic conditions - You have active serious infections or other cancers - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.